ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ELTX vs CTOR // RSI-14 & 200D SMA MOMENTUM

Elicio Therapeutics Inc. (NASDAQ) VS. Citius Oncology Inc. (NASDAQ) • 15-METRIC TALLY: ELTX 2 — CTOR 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ELTX
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ELTX VS. CTOR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ELTX CTOR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -11.16% — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 ELTX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 41.3 29.1 +12.20 ELTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $47.4M $49.2M -$1.8M CTOR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ELTX REV CTOR REV ELTX GROSS % CTOR GROSS % ELTX FCF CTOR FCF
FY 2025 $0 $0 — — -$37.0M -$5.5M
FY 2024 $0 $0 — — -$37.2M $126.4K
FY 2023 $0 $0 — — -$32.7M -$601.3K
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ELTX // BETA —
CTOR // BETA —